SMS-oncology opens new office in Frankfurt, Germany
SMS-ONCOLOGY, a full-service clinical CRO solely dedicated to oncology, is pleased to announce the opening of a new office and the establishment or subsidiary company: SMS-oncology GmbH.
SMS-oncology, Europe’s leading oncology CRO, opened the doors of its new office in Frankfurt, Germany. SMS-oncology GmbH is ideally situated in one of the major oncology biotech hubs within Europe and in the vicinity of Frankfurt Airport. SMS-oncology operates in over 20 countries from its headquarters at Schiphol Airport in the Netherlands, and has established local presence in the Nordics, Spain and now Germany. The new office accommodates the growing team of oncology drug development specialists.
The new German entity SMS-oncology GmbH will be led by Managing Director Mr. Raymond Hoffmans, who has 15 years of experience in cancer research. After receiving his PhD from the University of Zurich (Switzerland), he joined the Dana Farber Cancer Institute in Boston (US) as a postdoctoral research fellow. In 2009, he returned to the Netherlands to join the Hubrecht Institute in Utrecht, before he moved to SMS oncology about 9 years ago. Since 2014, Raymond has been Chief Business Development Officer at SMS-oncology, a position he will combine with his new role of Managing Director of the GmbH.
Raymond: “We are very proud and pleased to announce the opening of our new office in Frankfurt. We experienced strong organic growth over the past years. The current opening of our GmbH office is the perfect next step in line with our business planning of international expansion.”
He continues: “The expansion will not only allow us to be closer to our clients and the medical sites we work with but will also allow us to provide more tailored solutions to the individual needs of our clients.”
Ms. Philine van den Tol, Chief Executive Officer of SMS oncology, said: “We are delighted to bring the company one step closer in achieving our ambitious goal of becoming the go-to oncology specialist CRO in the world. This is another step forward in our mission to excel in oncology trials for the benefit of our clients and cancer patients worldwide.”
SMS-oncology GmbH address: